![Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors - Annals of Oncology Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/8fc38758-d8e7-4796-879e-95a8dc906a6c/gr1.jpg)
Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors - Annals of Oncology
![Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours - European Journal of Cancer Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours - European Journal of Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/79549895-0c20-48d6-b386-5a10bec34a42/gr1_lrg.jpg)
Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours - European Journal of Cancer
![Plasma MIP-1β levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib - Lung Cancer Plasma MIP-1β levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib - Lung Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2d1d2a54-c482-4653-9151-699da0a4ead5/gr1.gif)
Plasma MIP-1β levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib - Lung Cancer
![Cells | Free Full-Text | Boosting the Immune Response—Combining Local and Immune Therapy for Prostate Cancer Treatment | HTML Cells | Free Full-Text | Boosting the Immune Response—Combining Local and Immune Therapy for Prostate Cancer Treatment | HTML](https://www.mdpi.com/cells/cells-11-02793/article_deploy/html/images/cells-11-02793-g001.png)
Cells | Free Full-Text | Boosting the Immune Response—Combining Local and Immune Therapy for Prostate Cancer Treatment | HTML
![PTEN Regulates PDGF Ligand Switch for β-PDGFR Signaling in Prostate Cancer - The American Journal of Pathology PTEN Regulates PDGF Ligand Switch for β-PDGFR Signaling in Prostate Cancer - The American Journal of Pathology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/27a9a3f3-6866-4391-b87e-68e4062536b0/gr1.jpg)
PTEN Regulates PDGF Ligand Switch for β-PDGFR Signaling in Prostate Cancer - The American Journal of Pathology
![PDF) Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer PDF) Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer](https://i1.rgstatic.net/publication/8400090_Determinants_of_Tumor_Response_and_Survival_With_Erlotinib_in_Patients_With_Non-Small-Cell_Lung_Cancer/links/0c96052658a9b6a411000000/largepreview.png)
PDF) Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer
![Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors | British Journal of Cancer Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fsj.bjc.6601550/MediaObjects/41416_2004_Article_BF6601550_Fig1_HTML.jpg)